MMR2 immunization at 4 to 5 years and 10 to 12 years of age: A comparison of adverse clinical events after immunization in the vaccine safety datalink project

Pediatrics

Volumn 100, Issue 5, 1997, Pages 767-771

  Davis, Robert L ^a,j   Marcuse, Edgar ^b   Black, Steven ^c   Shinefield, Henry ^c   Givens, Ben ^a   Schwalbe, Joan ^c   Ray, Paula ^c   Thompson, Robert S ^a   Chen, Robert ^d   Glasser, John W ^d   Rhodes, Philip H ^d   Swint, Emmett ^d   Jackson, Lisa A ^e   Barlow, William E ^e   Immanuel, Virginia H ^e   Benson, Patti J ^e   Mullooly, John P ^f   Drew, Lois ^f   Mendius, Barbara ^f   Lewis, Ned ^c   Fireman, Bruce H ^c   Ward, Joel I ^g   Vadheim, Connie M ^g   Marcy, S Michael ^g   Jing, Jennie ^g   Wulfson, Michael ^g   Lugg, Marlene ^c   Osborne, Patricia ^c   Wise, Robert P ^h   Rastogi, Suresh ^h   Patriarca, Peter ^h   Caserta, Vito ⁱ   more..

^a CENTER FOR HEALTH STUDIES   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c KAISER PERMANENTE   (United States)

^d CENTERS FOR DIS CONTR AND PREV   (United States)

^e Grp Hlth Coop of Puget Sound   (United States)

^f Northwest Kaiser Permanente ^*  (United States)

^g HARBOR UCLA MEDICAL CENTER   (United States)

^h CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

ⁱ Hlth Rsrc and Serv Administration   (United States)

^j Grp Hlth Coop Ctr Hlth Studs   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ARTICLE; CHILD; DOSE RESPONSE; DRUG SAFETY; EDEMA; FEMALE; FEVER; HUMAN; IMMUNIZATION; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALAISE; MALE; MEASLES; MUMPS; PRIORITY JOURNAL; RASH; RUBELLA; SEIZURE; THROMBOCYTOPENIA;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; MALE; MEASLES VACCINE; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS VACCINE; RUBELLA VACCINE; VACCINES, COMBINED;

EID: 0030734577     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.100.5.767     Document Type: Article

References (14)

1. Centers for Disease Control. Recommendations of the Immunization Practices Advisory Committee (ACIP). Measles Prevention. MMWR. 1989;38:1-13
2. American Academy of Pediatrics. Measles. In: Peter G, 1994 Red Book. Report of the Committee on Infectious Diseases. 23rd ed. Elk Grove Village, IL: American Academy of Pediatrics; 1994:308-322
3. Markowitz LE, Katz SL. Measles vaccine. In: Plotkin SA, Mortimer EA Jr, eds. Vaccines. Philadelphia, PA: WB Saunders; 1994:229-276
4. Cochi SL, Wharton M, Plotkin SA. Mumps vaccine. In: Plotkin SA, Mortimer EA Jr, eds. Vaccines. Philadelphia, PA: WB Saunders; 1994: 277-301
5. Swartz TA, Klingber W, Goldwasser RA, Klingber MA, Goldblum N, Hilleman MR. Clinical manifestations, according to age, among females given HPV-77 duck rubella vaccine. Am J Epidemiol. 1971;94:246-251
6. Weibel RE, Stokes J, Buynak EB, Hilleman MR. Influence of age on clinical response to HPV-77 duck rubella vaccine. JAMA. 1972;202: 805-807
7. Chen RT, Glasser JW, Rhodes PH, et al. Vaccine Safety Datalink Project: a new tool for improving vaccine safety monitoring in the United States. Pediatrics. 1997;99:765-773
8. Fine PE, Chen RT. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol. 1992;136:121-135
9. Babbott FL Jr, Gordon JE. Modern measles. Am J Med Sci. 1954;228: 334-361
10. Black FL. Measles. In: Evans AS, ed. Viral Infections of Humans. Epidemiology and Control. 3rd ed. New York, NY: Plenum; 1989:451-465
11. Barkin RM. Measles mortality: a retrospective look at the vaccine era. Am J Epidemiol. 1975;102:341-349
12. Barkin RM. Measles mortality. Analysis of the primary cause of death. JAMA. 1975;129:307-309
13. Markowitz LE, Preblud SR, Fine PE, Orenstein WA. Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J. 1990;9:101-110
14. Anders JF, Jacobson RM, Poland GA, Jacobsen SJ, Wollan PC. Secondary failure rates of measles vaccines: a metaanalysis of published studies. Pediatr Infect Dis J. 1996;15:62-66